CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

1. Pivot, X.
2. Manikhas, A.
3. Zurawski, B.
4. Chmielowska, E.
5. Karaszewska, B.
6. Allerton, R.
7. Chan, S.
8. Fabi, A.
9. Bidoli, P.
10. Gori, S.
11. Ciruelos, E.
12. Dank, M.
13. Hornyak, L.
14. Margolin, S.
15. Nusch, A.
16. Parikh, R.
17. Nagi, F.
18. DeSilvio, M.
19. Santillana, S.
20. Swaby, R.F.
21. Semiglazov, V.